<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594825</url>
  </required_header>
  <id_info>
    <org_study_id>Valsartan</org_study_id>
    <nct_id>NCT03594825</nct_id>
  </id_info>
  <brief_title>Nighttime Valsartan in Hemodialysis Hypertension</brief_title>
  <acronym>NVHH</acronym>
  <official_title>Effect of Nighttime Valsartan on Prognosis of Nocturnal Hypertension Patients Undergoing Maintenance Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fifth Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fifth Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertension is one of the most important independent risk factors for the prognosis of
      maintenance hemodialysis patients. The incidence rate is high and the control rate is low.
      Nocturnal hypertension has been paid more attention in recent years. Compared to daytime
      blood pressure, nocturnal blood pressure is an independent and efficient prognostic indicator
      of hypertensive deaths and cardiovascular events, but it's lack of evidence about its impact
      on prognosis in hemodialysis patients and the effective treatment program. Our previous
      cohort study suggests that the incidence of nocturnal hypertension in patients with chronic
      kidney disease is up to 71.22%, with a significant increase as the decline of renal function,
      and more severe target organ damage in patients with nocturnal hypertension: the decrease of
      glomerular filtration rate, left ventricular hypertrophy, and the increase of all cause death
      and cardiovascular death. Our small sample size study show that night time antihypertensive
      drugs can better control blood pressure and delay the development of left ventricular
      hypertrophy. These preliminary results suggest that nocturnal hypertension is closely related
      to the prognosis of chronic renal disease. Taking antihypertensive drugs at night is one of
      the options for controlling nocturnal hypertension. However, it is not clear whether taking
      antihypertensive drugs at night can improve the prognosis of maintenance hemodialysis
      patients with nocturnal hypertension. To this end, we collect maintenance hemodialysis
      patients with nocturnal hypertension, and propose a time selective use of valsartan to
      intervene in nocturnal hypertension. By comparing the differences in the effects of valsartan
      on the prognosis of maintenance hemodialysis patients during the day or night, to further
      clarify the role of nocturnal hypertension in the prognosis of maintenance hemodialysis
      patients, whether controlling nocturnal hypertension can improve the prognosis of maintenance
      hemodialysis patients. The completion of the study will optimize the prevention and treatment
      of hypertension in maintenance hemodialysis patients, and provide an evidence for precise
      prevention and treatment of hypertension in maintenance hemodialysis patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all-cause death</measure>
    <time_frame>5 years</time_frame>
    <description>death caused by all causes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiovascular death</measure>
    <time_frame>5 years</time_frame>
    <description>death caused by cardiovascular events, such as myocardial infarction, arrhythmia and heart failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cerebrovascular death</measure>
    <time_frame>5 years</time_frame>
    <description>death caused by cerebral vascular events, such as stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardio cerebral vascular events</measure>
    <time_frame>5 years</time_frame>
    <description>cardiovascular and cerebrovascular events that require hospitalization and lead to death or non death, including myocardial infarction, heart failure, stroke, vascular reconstruction, peripheral vascular disease, and non-traumatic amputation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>cardiovascular structural abnormalities</measure>
    <time_frame>5 years</time_frame>
    <description>changes of carotid artery intima-media thickness and left ventricular mass index</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Hypertension;Nephropathy</condition>
  <arm_group>
    <arm_group_label>nighttime group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with nocturnal hypertension taking valsartan at nighttime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>daytime group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with nocturnal hypertension taking valsartan at daytime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Different time of taking medicine</description>
    <arm_group_label>daytime group</arm_group_label>
    <arm_group_label>nighttime group</arm_group_label>
    <other_name>Novartis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age over 18 years old and &lt;75 years.

          2. Diagnosed as CKD 5th stage in accordance with the kdigo guide 2012 (egfr &lt; 15 ml/ (min
             1.73m2)).

          3. Accept 2-3 times a week, 4h regular hemodialysis for &gt;3 months.

          4. Ambulatory blood pressure monitoring indicates nighttime blood pressure systolic blood
             pressure(SBP) &gt; 120mmHg and / or diastolic blood pressure(DBP) &gt; 70mmHg.

        Exclusion Criteria:

          1. Stop hemodialysis longer than one month more than 2 times.

          2. Night learning or work, irregular rest for a long time.

          3. Overloading capacity, ultrafiltration volume of each treatment &gt;7% dry weight.

          4. Persistent atrial fibrillation.

          5. Severe anemia and severe dystrophy.

          6. Patients with postural hypotension or symptomatic hypotension.

          7. Severe side effects or contraindications of valsartan treatment.

          8. Treatment of corticosteroids or other hormones at present.

          9. Unable to cooperate or unable to tolerate ambulatory blood pressure monitoring.

         10. Ineffective ambulatory blood pressure data.

         11. The clinical data were incomplete during the treatment period; end-point events
             occurred within 6 months or follow-up time was less than 6 months.

         12. In the first 3 months before admission, there were obvious cardiovascular and
             cerebrovascular diseases such as coronary syndrome, myocardial infarction or stroke.

         13. There were complications such as vascular disease, infection and bleeding within 1
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng Wang, Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology Department, the Fifth Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianting Ke, Doctor</last_name>
    <phone>0086 756 2528953</phone>
    <email>kjt1997@163.com</email>
  </overall_contact>
  <reference>
    <citation>K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005 Apr;45(4 Suppl 3):S1-153.</citation>
    <PMID>15806502</PMID>
  </reference>
  <reference>
    <citation>Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, Gallagher M, Roberts MA, Cass A, Neal B, Perkovic V. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009 Mar 21;373(9668):1009-15. doi: 10.1016/S0140-6736(09)60212-9. Epub 2009 Feb 25. Review.</citation>
    <PMID>19249092</PMID>
  </reference>
  <reference>
    <citation>Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension. 2009 May;53(5):860-6. doi: 10.1161/HYPERTENSIONAHA.108.128116. Epub 2009 Mar 9. Review.</citation>
    <PMID>19273737</PMID>
  </reference>
  <reference>
    <citation>Nakai S, Masakane I, Akiba T, Iseki K, Watanabe Y, Itami N, Kimata N, Shigematsu T, Shinoda T, Syoji T, Syoji T, Suzuki K, Tsuchida K, Nakamoto H, Hamano T, Marubayashi S, Morita O, Morozumi K, Yamagata K, Yamashita A, Wakai K, Wada A, Tsubakihara Y. Overview of regular dialysis treatment in Japan (as of 31 December 2005). Ther Apher Dial. 2007 Dec;11(6):411-41.</citation>
    <PMID>18028170</PMID>
  </reference>
  <reference>
    <citation>Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003 Sep;115(4):291-7.</citation>
    <PMID>12967694</PMID>
  </reference>
  <reference>
    <citation>Liu W, Ye H, Tang B, Song Z, Sun Z, Wen P, Yang J. Profile of interdialytic ambulatory blood pressure in a cohort of Chinese patients. J Hum Hypertens. 2014 Nov;28(11):677-83. doi: 10.1038/jhh.2014.41. Epub 2014 Jun 12.</citation>
    <PMID>24919753</PMID>
  </reference>
  <reference>
    <citation>Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, BÃ¶hm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press. 2014 Feb;23(1):3-16. doi: 10.3109/08037051.2014.868629. Epub 2013 Dec 20.</citation>
    <PMID>24359485</PMID>
  </reference>
  <reference>
    <citation>Hodgkinson J, Mant J, Martin U, Guo B, Hobbs FD, Deeks JJ, Heneghan C, Roberts N, McManus RJ. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. BMJ. 2011 Jun 24;342:d3621. doi: 10.1136/bmj.d3621. Review.</citation>
    <PMID>21705406</PMID>
  </reference>
  <reference>
    <citation>Fagard RH, Staessen JA, Thijs L. Relationships between changes in left ventricular mass and in clinic and ambulatory blood pressure in response to antihypertensive therapy. J Hypertens. 1997 Dec;15(12 Pt 1):1493-502.</citation>
    <PMID>9431857</PMID>
  </reference>
  <reference>
    <citation>Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, Pessina A, Porcellati C, Rappelli A, Salvetti A, Trimarco B. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation. 1997 Mar 18;95(6):1464-70. Erratum in: Circulation 1997 Aug 5;96(3):1065. Agebiti-Rosei, E [corrected to Agabiti-,E]; Pessino, A [corrected to Pessina, A].</citation>
    <PMID>9118514</PMID>
  </reference>
  <reference>
    <citation>Cuspidi C, Sala C, Valerio C, Negri F, Mancia G. Nocturnal blood pressure in untreated essential hypertensives. Blood Press. 2011 Dec;20(6):335-41. doi: 10.3109/08037051.2011.587280. Epub 2011 Jun 9.</citation>
    <PMID>21651423</PMID>
  </reference>
  <reference>
    <citation>Hoshide S, Ishikawa J, Eguchi K, Ojima T, Shimada K, Kario K. Masked nocturnal hypertension and target organ damage in hypertensives with well-controlled self-measured home blood pressure. Hypertens Res. 2007 Feb;30(2):143-9.</citation>
    <PMID>17460384</PMID>
  </reference>
  <reference>
    <citation>Yano Y, Kario K. Nocturnal blood pressure and cardiovascular disease: a review of recent advances. Hypertens Res. 2012 Jul;35(7):695-701. doi: 10.1038/hr.2012.26. Epub 2012 Mar 1. Review.</citation>
    <PMID>22378470</PMID>
  </reference>
  <reference>
    <citation>Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, Van Der Niepen P, O'Brien E; Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003 Jun 12;348(24):2407-15.</citation>
    <PMID>12802026</PMID>
  </reference>
  <reference>
    <citation>Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension. 2011 Jan;57(1):3-10. doi: 10.1161/HYPERTENSIONAHA.109.133900. Epub 2010 Nov 15. Review.</citation>
    <PMID>21079049</PMID>
  </reference>
  <reference>
    <citation>Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro C, Halimi JM, Heine G, Jadoul M, Jarraya F, Kanbay M, Mallamaci F, Mark PB, Ortiz A, Parati G, Pontremoli R, Rossignol P, Ruilope L, Van der Niepen P, Vanholder R, Verharr MC, Wiecek A, Wuerzner G, London GM, Zoccali C. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). J Hypertens. 2017 Apr;35(4):657-676. doi: 10.1097/HJH.0000000000001283.</citation>
    <PMID>28157814</PMID>
  </reference>
  <reference>
    <citation>Kishi T, Hirooka Y, Konno S, Sunagawa K. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome. J Hypertens. 2012 Aug;30(8):1646-55. doi: 10.1097/HJH.0b013e328355860e.</citation>
    <PMID>22728908</PMID>
  </reference>
  <reference>
    <citation>Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008 Sep;52(3):501-6. doi: 10.1053/j.ajkd.2008.04.031. Epub 2008 Jul 24.</citation>
    <PMID>18653268</PMID>
  </reference>
  <reference>
    <citation>Wang C, Zhang J, Liu X, Li CC, Ye ZC, Peng H, Chen Z, Lou T. Effect of valsartan with bedtime dosing on chronic kidney disease patients with nondipping blood pressure pattern. J Clin Hypertens (Greenwich). 2013 Jan;15(1):48-54. doi: 10.1111/jch.12021. Epub 2012 Oct 9.</citation>
    <PMID>23282124</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 4, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>July 19, 2018</last_update_submitted>
  <last_update_submitted_qc>July 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fifth Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Cheng Wang</investigator_full_name>
    <investigator_title>Director of Nephrology</investigator_title>
  </responsible_party>
  <keyword>Nocturnal Hypertension; Hemodialysis; Valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

